title: Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?
authors: Section of Pharmacology and University Center DIFF-Drug Innovation Forward Future, Department of Molecular and Translational Medicine, University of Brescia, Brescia giandomenicoroviello@gmail.com.|Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Cremona.
authors: G
authors: G
authors: Roviello
authors: Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Cremona.|Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
authors: D
authors: D
authors: Generali
mesh_terms: D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms; D064129:Prostatic Neoplasms, Castration-Resistant
chemical_list: D017430:Prostate-Specific Antigen